Oxa-noribogaine developers will achieve a sustained public market or disclosed private valuation premium of 40%+ over comparable raw ibogaine-focused companies within 12 months of 2026-05-01.

Companies developing oxa-noribogaine (a safer chemical cousin of ibogaine) will be valued at least 40% higher than companies focusing only on raw ibogaine, within one year of May 2026. This matters to investors because it signals which version of the drug the market thinks will actually work and get approved.

The cardiac safety bifurcation thesis is directionally sound but the 40% premium threshold is highly specific and hard to measure cleanly given illiquid private markets and small public floats. Comparator selection is contested. Even if the bifurcation is real, noisy markets and idiosyncratic company-level factors (pipeline milestones, fundraising events) make this specific threshold uncertain. Confidence reduced materially. Prediction is retained because it is falsifiable in principle via disclosed valuations or public market caps.